Sei Investments Co. raised its stake in Maximus, Inc. (NYSE:MMS) by 941.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,240 shares of the health services provider’s stock after buying an additional 42,706 shares during the period. Sei Investments Co. owned approximately 0.07% of Maximus worth $2,958,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. American International Group Inc. increased its stake in shares of Maximus by 4.1% in the first quarter. American International Group Inc. now owns 166,652 shares of the health services provider’s stock valued at $10,366,000 after buying an additional 6,634 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Maximus by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 16,400 shares of the health services provider’s stock valued at $1,020,000 after buying an additional 400 shares in the last quarter. OppenheimerFunds Inc. increased its stake in shares of Maximus by 19.5% in the first quarter. OppenheimerFunds Inc. now owns 11,010 shares of the health services provider’s stock valued at $685,000 after buying an additional 1,793 shares in the last quarter. Advantus Capital Management Inc increased its stake in shares of Maximus by 3.1% in the first quarter. Advantus Capital Management Inc now owns 8,298 shares of the health services provider’s stock valued at $516,000 after buying an additional 248 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Maximus by 6.9% in the first quarter. Geode Capital Management LLC now owns 496,870 shares of the health services provider’s stock valued at $30,905,000 after buying an additional 31,918 shares in the last quarter. 97.20% of the stock is owned by hedge funds and other institutional investors.
Shares of Maximus, Inc. (NYSE:MMS) opened at 59.90 on Wednesday. Maximus, Inc. has a 1-year low of $43.69 and a 1-year high of $64.97. The stock has a market capitalization of $3.89 billion, a P/E ratio of 19.20 and a beta of 1.39. The stock’s 50 day moving average price is $60.69 and its 200-day moving average price is $61.12.
Maximus (NYSE:MMS) last released its earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.03. Maximus had a return on equity of 25.08% and a net margin of 8.43%. The business had revenue of $600.40 million for the quarter, compared to analyst estimates of $614.12 million. During the same quarter in the prior year, the company posted $0.79 earnings per share. Maximus’s revenue was down 2.7% on a year-over-year basis. Equities research analysts anticipate that Maximus, Inc. will post $3.12 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, August 31st. Investors of record on Tuesday, August 15th will be issued a dividend of $0.045 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $0.18 annualized dividend and a yield of 0.30%. Maximus’s payout ratio is presently 5.73%.
MMS has been the subject of several research analyst reports. Zacks Investment Research downgraded Maximus from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. KeyCorp reissued a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. Maxim Group downgraded Maximus from a “buy” rating to a “hold” rating and set a $66.00 price objective for the company. in a research note on Thursday, May 4th. They noted that the move was a valuation call. ValuEngine downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Finally, Jefferies Group LLC downgraded Maximus from a “buy” rating to a “hold” rating and increased their price objective for the stock from $63.00 to $64.00 in a research note on Friday, May 5th. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Maximus currently has a consensus rating of “Hold” and an average price target of $62.17.
In other Maximus news, General Counsel David Francis sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $58.89, for a total transaction of $117,780.00. Following the transaction, the general counsel now owns 13,716 shares of the company’s stock, valued at $807,735.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Richard A. Montoni sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $62.81, for a total value of $1,884,300.00. Following the transaction, the chief executive officer now directly owns 584,114 shares in the company, valued at approximately $36,688,200.34. The disclosure for this sale can be found here. Insiders have sold 148,342 shares of company stock worth $9,131,917 in the last quarter. 3.10% of the stock is currently owned by corporate insiders.
About Maximus
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS).
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
